DNAM-1 immunoreceptor integrates innate and adaptive immune programs to drive intestinal inflammation

Authors:

Abstract
Summary: Innate and adaptive immune responses play critical roles in the pathogenesis of inflammatory bowel disease (IBD), yet the molecular pathways integrating these responses remain elusive. Here, we identify DNAM-1 immunoreceptor as a central driver of colitis through distinct, cell type–specific mechanisms. Transcriptomic analyses of human and murine group 3 innate lymphoid cells (ILC3s) revealed DNAM-1 as a conserved IL-23–responsive surface molecule associated with inflammatory cytokine production. In an innate immune–driven anti-CD40 monoclonal antibody (mAb)–induced colitis model, DNAM-1 expressed on ILC3s promoted intestinal inflammation by enhancing IL-22 and GM-CSF production via the integration of the Akt–mTORC1–HIF-1α signaling pathway. Genetic ablation or antibody-mediated blockade of DNAM-1 attenuated inflammatory cytokine production and disease severity. Paradoxically, in T cell–dependent colitis, DNAM-1 expression on dendritic cells, but not on ILC3s or CD4⁺ T cells, exacerbated disease by promoting dendritic cell activation and pathogenic Th1 and Th17 differentiation. Notably, therapeutic blockade of DNAM-1 ameliorated disease in both colitis models and exerted complementary effects when combined with anti-TNF therapy, accompanied by modulation of immune activation programs distinct from those regulated by TNF inhibition. Collectively, these findings establish DNAM-1 as a pivotal regulator of intestinal inflammation bridging innate and adaptive immunity and identify DNAM-1 blockade as a next-generation therapeutic strategy for IBD. Highlight: ► DNAM-1 is an IL-23-responsive receptor conserved in human and mouse ILC3s. ► DNAM-1 on ILC3s drives innate colitis via Akt-mTORC1-HIF-1α signaling. ► DNAM-1 on DCs promotes T cell-dependent colitis by inducing Th1/Th17 cells. ► DNAM-1 blockade targets immune pathways distinct from TNF inhibition. ► Combined DNAM-1 and TNF blockade shows additive therapeutic efficacy in colitis.
Funding Information
  • Japan Society for the Promotion of Science (21H04836)
  • Japan Society for the Promotion of Science (21K19469)
  • Japan Society for the Promotion of Science (16H05169)
  • Japan Society for the Promotion of Science (21K15462)
  • JST SPRING (JPMJSP2124)